Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) Sees Significant Decrease in Short Interest

Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 1,435,500 shares, a decline of 13.8% from the August 31st total of 1,665,000 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Jacobio Pharmaceuticals Group Price Performance

JBPHF remained flat at $0.30 during trading on Monday. Jacobio Pharmaceuticals Group has a twelve month low of $0.30 and a twelve month high of $0.30. The stock has a 50 day simple moving average of $0.30 and a 200 day simple moving average of $0.30.

Jacobio Pharmaceuticals Group Company Profile

Jacobio Pharmaceuticals Group Co, Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein.